A needle in
For doctors in primary care, detecting brain cancer has been likened to searching for a needle in a haystack.
Typically, patients present with non-specific symptoms; the vast majority of which are not life threatening.
Spotting cancer is difficult and referring patients to hospital for expensive brain scans is not always immediately possible.
BRAIN TUMORS REDUCE
LIFE EXPECTANCY
BY ON AVERAGE 20 YEARS.
Worldwide, over 86,000 cases each year, with the highest per-patient initial cost of care than any cancer group.
8/10 brain tumor patients had to stop working completely or reduce hours.
38% of patients in the UK have five visits to primary care before diagnosis.
Early
accurate
diagnosis
With the Dxcover spectroscopic liquid biopsy, doctors will finally have a fast, inexpensive, and easy way to accurately test for brain cancer and reduce delays in referral and waiting times.
Earlier diagnosis results in significantly higher survival rates compared to late-stage diagnosis, with treatment options and the chances of recovery and better quality of life hugely increased.
The Dxcover Brain Cancer Liquid Biopsy test can aid doctors and clinicians with patient management, allowing them to prioritise and fast-track the most appropriate and effective treatments.
EARLY DIAGNOSIS IS VITAL TO IMPROVING SURVIVAL RATES AND QUALITY OF LIFE.
Understanding the Barriers to Brain Tumor Diagnosis
Dxcover participated in a roundtable discussion hosted by The Brain Tumour Charity, examining the challenges in early diagnosis and access to care for brain tumor patients in Scotland. This report highlights key barriers and potential solutions to improve patient outcomes.